Elutia, Inc. Stock Plummets to New 52-Week Low of $1.13

Elutia, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.13 on September 17, 2025. This significant decline marks a stark contrast to its 52-week high of USD 5.12, reflecting a challenging year for the company, which has seen its stock price plummet by 67.44% over the past year.
The company's market capitalization stands at approximately USD 80 million, and it currently operates at a loss, with no dividend yield. Financial metrics indicate a negative book value and a concerning debt-to-equity ratio of -0.62, suggesting difficulties in managing its financial obligations. Elutia's return on equity is notably high at 67.24%, yet this is overshadowed by its declining net sales, which have contracted at an annual rate of 15.13% over the last five years.

Recent financial results have also been underwhelming, with operating cash flow hitting a low of USD -32.8 million and a pre-tax profit of USD -7.83 million. The company's performance has consistently lagged behind the S&P 500, highlighting ongoing challenges in both short-term and long-term growth prospects.